Work

Evobrutinib Efficacy is Maintained Over Two Years in an Open-label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis (4124)

Year: 2021

Type: article

Source: Neurology

DOI: 10.1212/wnl.96.15_supplement.4124

Authors: Xavier Montalban, Douglas L. Arnold, Martin S. Weber, Ivan Staikov, Karolina Piasecka-Stryczynska, Emily C. Martin, Matthew Mandel, Fernando Dangond, Jerry S. Wolinsky

Institutions: Vall d'Hebron Hospital Universitari, Montreal Neurological Institute and Hospital, University of Göttingen, Tokuda Hospital, Acibadem City Clinic, Poznan University of Medical Sciences, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), The University of Texas Health Science Center at Houston

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3205572691

FWCI: 0.833

Cites:

Cited by: 5

Related to: 10